Ultimately, clinical trials such as these have confirmed that, similar to sodium/glucose cotransporters 2 (SGLT2) inhibitors, GLP‐1 mimetics have established cardiovascular disease benefits in diabetes. This evidence concerns the gene GCG and cardiovascular disorder.